SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending as community members rally around its potential within the Ethereum ecosystem, citing a unique narrative and strong community-driven momentum. Many believe $YEE is poised for a significant breakout, drawing comparisons to past meme coin successes and highlighting its potential for substantial growth. Enthusiasts are actively encouraging others to 'study' $YEE and join the movement, emphasizing its connection to the resurgence of ETH.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining traction due to its high throughput, processing millions of transactions per second, and its potential to become a compliant infrastructure solution for traditional finance. The project's interoperability with other chains and integration with a Stripe company, Bridge, are also key talking points. Community discussions revolve around Keeta's infrastructure edge and possible undervaluation compared to competitors.

BYD Co., Ltd. engages in the research, development, manufacture, and sale of rechargeable batteries and photovoltaic business. It operates through the following segments: Rechargeable Batteries and Photovoltaic Products, Mobile Handset Components, Assembly Service and Other Products, and Automobiles and Related Products and Other Products. The Rechargeable Batteries and Photovoltaic Products segment is involved in the manufacture and sale of lithium-ion batteries and nickel batteries, photovoltaic products, and iron batteries products for mobile phones, electric tools, and other portable electronic instruments, photovoltaic products, energy storage products, and electric vehicles. The Mobile Handset Components, Assembly Service and Other Products segment focuses on the sale of mobile handset components such as housings, electronic components, assembly services, and medical protection products. The Automobiles and Related Products and Other Products segment consists of automobiles and auto-related moulds and components and automobile leasing and after sales services, rail transport related business, and medical protection products. The company was founded by Chuan Fu Wang on February 10, 1995 and is headquartered in Shenzhen, China.

BYD Co - ADR

BYD Co Ltd/ADR

BYD is trending due to its unveiling of a new super-charging EV technology platform, boasting near instantaneous charging capabilities. The company is also experiencing record profits and revenue, while some analysts suggest it's outcompeting Tesla in key markets. Community members are weighing the potential impact on the EV sector and BYD's growing global presence.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending due to a convertible note offering, sparking community debate about the company's debt and future prospects. While some investors express concern over potential dilution and financial health, others view the offering as a strategic move for long-term growth in the AI cloud sector. Discussions also revolve around CRWV's competitive positioning and potential impact from broader industry news, like Oracle's earnings.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola (KO) is trending as investors discuss a leadership transition with Henrique Braun named as the next CEO in 2026. While some view the change as unlikely to cause volatility, others are analyzing the stock's technicals, with community chatter focused on potential shakeouts and key support levels. Some traders are eyeing potential bullish reversals given oversold conditions, while others express frustration with the stock's price action and debate its premium valuation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate earnings and potential updates on QNX technology, with the community showing increasing optimism for QNX's long-term potential in the automotive and IoT sectors. Bullish sentiment is further fueled by technical signals like golden crosses and wedge formations. Community members express growing confidence in the company's future revenue and profitability.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar ($PSNY) is trending amid discussions of a potential reverse stock split and overall financial health, with some traders pointing out a possible short squeeze due to limited share availability and upcoming reporting this week. Despite some positive sentiment around sales numbers, the community is also discussing potential red flags on the balance sheet, high cash burn, and concerns about the stock's long-term viability within the competitive EV sector.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending as investors digest the potential impact of its partnership with Google to build AI data centers in space, dubbed "Project Suncatcher". The community views this as a game-changer that could transform Planet Labs into a space infrastructure company, driving long-term revenue growth beyond satellite imagery. Bullish sentiment is high, with some speculating about a possible acquisition by Google and significant price appreciation.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

ONDO is trending as the community discusses its potential in the tokenized real-world asset (RWA) space and upcoming catalysts. Speculation surrounds possible integrations with traditional finance, including potential partnerships with BlackRock and the launch of tokenized stocks. Some traders are closely watching a large token unlock event in January 2026.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending due to discussions around a $400 million AI deal with Perplexity, set to integrate AI search into Snapchat by 2026. The community is debating CEO Evan Spiegel's leadership and share sales, while also considering the impact of potential social media bans for under-16s in Australia. Overall, sentiment is mixed, with some anticipating a strong 2026 driven by AI and new specs, while others express concerns about profitability and management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare ETF (IYH) Hits New 52-Week High

IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.

<ul class="summary-bullets"><li>Prasad, who oversees gene therapies in the FDA, told Bloomberg that regulation needs to evolve as science develops.</li><li>The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. &nbsp;</li></ul>A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.Vinay Prasad, who oversees gene therapies in the U.S. Food and Drug Administration, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-31/fda-clears-way-for-faster-personalized-gene-editing-treatments">told</a> Bloomberg that regulation needs to evolve as science develops. Prasad reportedly added that scientific advances like Nobel prize-winning CRISPR gene-editing technology have forced the agency to relax some of its strict rules.The agency is “going to be extremely flexible and work very fast with the scientists who want to bring these therapies to kids who need it,” Prasad told Bloomberg.The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. Prasad expects it will spark interest in developing treatment for rare diseases.<h2 class="st-heading-2">CRISPR’s Potential</h2>CRISPR gene editing is a technology that allows scientists to modify an organism's DNA precisely. It involves a guide RNA that directs a DNA-cutting enzyme to a specific target in the DNA for it to make a cut. The cell's natural repair process either inactivates the gene or allows scientists to insert a new piece of DNA.Earlier this year, an infant named KJ Muldoon, born with a rare genetic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, was successfully treated with a customized CRISPR gene editing therapy by a team at the Children’s Hospital of Philadelphia.The team behind the treatment of the infant is now designing clinical trials that can be used to gain FDA approval with a gene-editing platform that can be tailored for patients with different genetic mutations, Bloomberg reported. The team is asking for FDA permission to start clinical trials for a liver disorder known as phenylketonuria and urea cycle disorders, the report added.These diseases can be treated by editing genes in the liver, a known target for CRISPR, team members told Bloomberg.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ardelyx-shares-soar-premarket-as-ceo-sees-continued-demand-for-blockbuster-drug-ibsrela/cLGqRUcR3Ur">Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 

Equity

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 


UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


President Donald Trump on Monday called on the Democrats to end the government shutdown, which is now in its sixth day, while also expressing his willingness to negotiate with them on healthcare, the key sticking point.In a Truth Social post, Trump&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115329671584864920">said</a>, “Democrats have SHUT DOWN the United States Government right in the midst of one of the most successful Economies, including a Record Stock Market, that our Country has ever had.” The president lamented that this has affected several programs, services and other things the Americans rely on, adding that “It should not have happened.After the Republicans and Democrats could not agree on a stopgap funding deal, the government has been shut down since the start of the fiscal year (October 1). In a report released last Wednesday, Morgan Stanley strategists stated that the possibility of permanent layoffs among federal workers, as well as delays in economic reports, could make the first shutdown in six years more consequential than previous instances.Notwithstanding the headwind, the stock market has been on a tear, clocking fresh highs in a trot. On Monday, all the major stock market gauges closed at fresh records, thanks to the boost provided by artificial intelligence (AI) news flow.For the year-to-date (YTD) period, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund (ETF) that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> have gained 15.6% and 19.3%, respectively. On Stocktwits, retail traders remained cautious, with the sentiment toward both the SPY and QQQ ETF remaining ‘bearish’ by late Monday. The message volume on the SPY stream remained ‘high,’ while that on the QQQ was at ‘normal’ levels.&nbsp;In his post, Trump said, “I am happy to work with the Democrats on their Failed Healthcare Policies, or anything else, but first they must allow our Government to reopen. In fact, they should open our Government tonight!”The failure to clinch a funding deal is primarily due to the Democrats’ insistence on extending healthcare funding, mainly the Obamacare subsidies that are set to expire. The expiration of healthcare funding would result in a sharp spike in the healthcare premiums Americans pay. Meanwhile, the Republicans want a plan to keep the government funded until Nov. 21 and negotiate spending policy only through the regular funding process.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/IYH">iShares U.S. Healthcare ETF (IYH)</a>, which is up about 5.4% YTD, attracted ‘neutral’ sentiment, a deterioration from the ‘bullish’ mood seen the day before, but the message volume stayed ‘high.’Earlier in the day, while talking to reporters in the Oval Office, Trump said, “We have a negotiation going on right now with the Democrats that could lead to very good things. And I’m talking about good things with regard to health care, the Hill <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://thehill.com/policy/healthcare/5541610-trump-democrats-healthcare-deal/">reported.</a> When asked if the Affordable Care Act (ACA), aka Obamacare Act, subsidies would be extended, the president said, “If we made the right deal, I’d make a deal. Sure.”“You have subsidies, that’s the problem with ObamaCare. The subsidies are so much, it’s billions and billions of dollars is being wasted. And we could have a much better health care than we have right now. And we’re talking to them. I’m not saying that’s going to happen.”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-vouches-for-microsoft-cloud-growth-with-675-price-target/ch6RQDgR3gw">Wells Fargo Vouches For Microsoft Cloud Growth With $675 Price Target On Stock</a>

U.S. President Donald Trump speaks in the Oval Office at the White House on October 06, 2025 in Washington, DC. 

Trump Says He's 'Happy To Work' With Democrats On 'Failed' Healthcare Policies, But Calls To End Government Shutdown 

The failure to clinch a funding deal is primarily due to the Democrats’ insistence on extending healthcare funding, mainly the Obamacare subsidies that are set to expire.

The looming&nbsp;U.S. government shutdown is seen as a significant headline risk for the market, which has been on an extended bull run. An absence of a deal&nbsp;regarding government funding among lawmakers by Sept. 30, when the fiscal year ends, could result in massive layoffs, further complicating the economic outlook.The standoff concerns a plan for discretionary funding for the upcoming fiscal year. On Sept. 19, a stopgap bill to fund the government through Nov. 21 failed to clear the Senate, where it needed 60 votes, after the Republican-controlled House passed it.An ongoing Stocktwits poll,&nbsp;in partnership with Polymarket, which asked platform users if the U.S. government would shut down this year, found that opinions were split equally. While 51% of the respondents said it&nbsp;was unlikely, 48% said it&nbsp;was likely to occur.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_2_12_08_AM_png_a52535d339.webp" alt="Screenshot 2025-09-29 at 2.12.08 AM.png">According to Polymarket, Stocktwits’ predictions market partner, the odds of a government shutdown have decreased to 72% from 80% as of Friday. The improved odds reflected optimism after reports, citing a White House official,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us/trump-meet-top-congressional-leaders-monday-white-house-official-says-2025-09-28/">stated</a> that President Donald Trump would meet with top lawmakers from both sides of the aisle on Monday to discuss government funding and avert a shutdown. Incidentally, the president cancelled a previous meeting with Rep. Hakeem Jeffries (D-N.Y.) and Sen. Chuck Schumer (D-N.Y.) to discuss the issue.&nbsp;The main area of contention is the Affordable Care Act tax credit subsidies, which are set to expire by the end of the year. While Democrats are fixated on discussing an extension as part of the negotiations, their Republican counterparts believe there is still time to address the issue.In his preview of the week ahead, economist Mohamed El-Erian said, “All eyes will be on Washington as the U.S. Congress attempts to iterate toward an agreement to avoid a government shutdown,”&nbsp;adding that&nbsp;much depends on the ongoing negotiations between the Trump Administration and Congressional leaders.In a joint statement, Democratic leaders Jefferies and Schumer confirmed Monday’s meeting with Trump and expressed their willingness to help resolve the crisis. “We are resolute in our determination to avoid a government shutdown and address the Republican healthcare crisis,” they said.The stock market has been chugging along nicely despite the multiple headwinds the economy is facing. The major indices trade just shy of their records, with the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund (ETF) that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> having risen 14% and 17%, respectively, year-to-date.On Stocktwits, sentiment toward both ETFs was ‘neutral’ as of early Monday, while the message volume on both streams remained at ‘high’ levels. The&nbsp;<a href="https://stocktwits.com/symbol/IYH">iShares U.S. Healthcare ETF (IYH)</a> is down 1% this year.&nbsp;Economists and market participants are mainly worried about the shutdown as investors close out the month and quarter, according to a MarketWatch <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/the-last-thing-the-stock-market-wants-right-now-is-a-government-shutdown-heres-why-7bac216e?mod=home_lead">report.</a> Charles Schwab investment strategist Kevin Gordon reportedly said, “This one could come at a really unfortunate time because we are supposed to get the jobs report on Friday,” adding that “If we don’t get access to that data, it’s going to be a problem.”The report also stated that Wells Fargo Global Strategist Gary Schlossberg said, “At the moment, we view the government shutdown on Oct. 1 as a high-probability event, likely lasting long enough to delay release of the September jobs [report] and, likely, CPI releases, due out October 3 and 15, respectively.”He sees any shutdown now as causing more extensive disruptions to data releases than the partial shutdown that occurred between December 2018 and January 2019 because more agencies are poised to be impacted by the lack of appropriation bills passed by Congress.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-s-paul-atkins-signals-fast-track-for-trump-plan-not-retreat-from-transparency/chDMru6R37X">Goodbye Quarterly Earnings? SEC’s Paul Atkins Signals Fast-Track For Trump Plan But Says It’s ‘Not A Retreat From Transparency’</a>

Tourists walk through the Rotunda in the U.S. Capitol Building on September 23, 2025 in Washington, DC. 

Retail Traders Evenly Split About Government Shutdown Odds: Strategists Weigh In On Whether Jobs Report Would Be Delayed Amid Looming Risk

The standoff concerns a plan for discretionary funding for the upcoming fiscal year.

US Government Shutdown Risk Splits Retail Traders — Strategists Warn Key Jobs Report Could Be Delayed

The standoff concerns a plan for discretionary funding for the upcoming fiscal year.


A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

BofA clients sold equities last week as buybacks slow

Investing.com -- Bank of America (BofA) clients turned net sellers of U.S. equities last week, pulling $1.4 billion from the market despite a 1.5% gain in the S&P 500.

Current Price	$64.88
Prev Close	$64.71
Open	$64.76
Dividend Yield	N/A
50-Day Moving Average	$62.69
Beta	N/A
Avg. Volume	691,604.68
PE Ratio	N/A

52-Week High	$66.91
52-Week Low	$53.35
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IYH
iShares US Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IYH News

IYHiShares US Healthcare ETF